1. Platelet aggregation at discharge: A useful tool in acute coronary syndromes?
- Author
-
Carlos Tavares, Gilberto P Marques, João Mariano Pego, Alda Reboredo, Margarida Lourenço, Graça Ribeiro, Luís A Providência, Francisco Rocha Gonçalves, Maria João Ferreira, Mário Freitas, Rogério Teixeira, Pedro Monteiro, and Sílvia Monteiro
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Ticlopidine ,Platelet Aggregation ,Platelet Function Tests ,medicine.medical_treatment ,Population ,Context (language use) ,Internal medicine ,Clinical endpoint ,medicine ,Humans ,Myocardial infarction ,Longitudinal Studies ,Prospective Studies ,Acute Coronary Syndrome ,education ,General Environmental Science ,education.field_of_study ,business.industry ,Unstable angina ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Clopidogrel ,Patient Discharge ,lcsh:RC666-701 ,Cardiology ,General Earth and Planetary Sciences ,Female ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,medicine.drug - Abstract
Introduction: Inhibition of platelet aggregation appears two hours after the first dose of clopidogrel, becomes significant after the second dose, and progresses to a steady-state value of 55% by day seven. Low response to clopidogrel has been associated with increased risk of stent thrombosis and ischemic events, particularly in the context of stable heart disease treated by percutaneous coronary intervention. Objective: To stratify medium-term prognosis of an acute coronary syndrome (ACS) population by platelet aggregation. Methods: We performed a prospective longitudinal study of 70 patients admitted for an ACS between May and August 2009. Platelet function was assessed by ADP-induced platelet aggregation using a commercially available kit (Multiplate® analyzer) at discharge. The primary endpoint was a combined outcome of mortality, non-fatal myocardial infarction, or unstable angina, with a median follow-up of 136.0 (79.0–188.0) days. Results: The median value of platelet aggregation was 16.0 U (11.0–22.5 U) with a maximum of 41.0 U and a minimum of 4.0 U (normal value according to the manufacturer: 53–122 U). After ROC curve analysis with respect to the combined endpoint (AUC 0.72), we concluded that a value of 18.5 U conferred a sensitivity of 75.0% and a specificity of 68% to that result. We therefore created two groups based on that level: group A – platelet aggregation
- Published
- 2012